Read More: ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment "Advanced Cell Technology, Inc.("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today confirmed that the vision of a patient enrolled in a clinical investigation of the company's retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment." Stem Cell Restored Vision To Blind Man Using Human Embryos "Stem cells restored the vision to a blind man who suffered from the degeneration of his retinal cells." Blindness eased by historic stem cell treatment "For the first time since they were discovered 13 years ago, human embryonic stem cells (hESCs) have shown medical promise." Embryonic stem cell trials for macular degeneration: a preliminary report "It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients."